Proton Beam Therapy
Proton Therapy for Anal Cancer
This trial is testing if Proton Therapy can reduce radiation exposure to healthy areas around anal cancer, aiming to lessen side effects compared to standard treatments. Proton therapy is an emerging treatment for cancer that may have distinct advantages over conventional radiotherapy, particularly in minimizing radiation dose to surrounding normal tissue.
Behavioral Intervention
Mind-Body Intervention for Female GI Cancer Survivors
This trial aims to gather feedback on a new intervention for female colorectal and anal cancer survivors. Up to 20 participants will receive the intervention and provide feedback on its acceptability, feasibility, and perceived
Radiation Therapy
Node-Sparing Chemo-Radiation for Anal Cancer
This trial is testing if skipping certain radiation treatments is as effective as giving them for early-stage anal cancer patients without lymph node involvement. The goal is to reduce side effects and improve quality of life.
Chemotherapy
Chemotherapy + Radiation for HIV-Associated Anal Cancer
This trial studies the effects of chemotherapy, radiation, and immunotherapy in treating HIV-associated anal cancer. It targets both low-risk and high-risk patients, aiming to kill cancer cells and help the immune system prevent the cancer from coming back.
Surgery
Surgery for Anal Cancer in HIV/AIDS Patients
This trial studies surgery to treat patients with small anal or perianal cancer who also have HIV. The surgery aims to safely remove the cancer with fewer side effects compared to other treatments. By cutting out the cancer, it helps prevent it from spreading or returning.
Popular Filters
Trials for Cervical Cancer Patients
Monoclonal Antibodies
Avelumab + Valproic Acid for Viral Associated Cancer
This trial is testing a combination of Valproic acid and Avelumab to treat cancers linked to chronic viral infections. Valproic acid helps reveal these hidden infections, while Avelumab keeps immune cells active to fight the cancer more effectively. Avelumab has shown promise in treating various cancers, including non-small cell lung cancer, genitourinary tumors, and urothelial carcinoma.
CAR T-cell Therapy
HPV Specific T Cells + Immunotherapy for Cancer
This trial is for people with HPV-associated cancers that have come back or have not gone away after standard treatment, or for whom standard treatment is not an option. The trial will test a new experimental treatment consisting of special immune system cells called HPVST cells.
CAR T-cell Therapy
E7 TCR-T Cells for HPV-Related Cervical and Throat Cancer
This trial tests a new treatment using modified immune cells to fight cancers caused by HPV. It targets patients with specific types of cancer linked to HPV who have a certain genetic marker. The treatment works by reprogramming the patient's immune cells to attack the cancer cells.
Trials for Vulvar Cancer Patients
CAR T-cell Therapy
HPV Specific T Cells + Immunotherapy for Cancer
This trial is for people with HPV-associated cancers that have come back or have not gone away after standard treatment, or for whom standard treatment is not an option. The trial will test a new experimental treatment consisting of special immune system cells called HPVST cells.
CAR T-cell Therapy
E7 TCR-T Cells for HPV-Related Cervical and Throat Cancer
This trial tests a new treatment using modified immune cells to fight cancers caused by HPV. It targets patients with specific types of cancer linked to HPV who have a certain genetic marker. The treatment works by reprogramming the patient's immune cells to attack the cancer cells.
Trials With No Placebo
Monoclonal Antibodies
Nivolumab + Chemotherapy for Anal Cancer
This trial is testing whether adding nivolumab to standard chemotherapy is more effective for patients with metastatic anal cancer. Nivolumab helps the immune system fight cancer, while chemotherapy kills or stops cancer cells from growing. Nivolumab has shown significant effectiveness in treating metastatic squamous cell carcinoma of the anal canal.
Monoclonal Antibodies
Avelumab + Valproic Acid for Viral Associated Cancer
This trial is testing a combination of Valproic acid and Avelumab to treat cancers linked to chronic viral infections. Valproic acid helps reveal these hidden infections, while Avelumab keeps immune cells active to fight the cancer more effectively. Avelumab has shown promise in treating various cancers, including non-small cell lung cancer, genitourinary tumors, and urothelial carcinoma.
View More Related Trials
Frequently Asked Questions
Introduction to anal cancer
What are the top hospitals conducting anal cancer research?
When it comes to advancing the treatment options for anal cancer, a number of top hospitals are making significant strides. In Kingman, Arizona, the Kingman Regional Medical Center is leading the way with three active clinical trials focused on this specific type of cancer. While their track record may be relatively new, having recorded their first trial in 2018, they are already demonstrating a commitment to finding innovative solutions.
On the West Coast, the University of California, San Francisco is also dedicated to tackling anal cancer through research and clinical trials. With three ongoing trials and four completed studies since their inaugural trial in 2008, this esteemed institution is making notable contributions towards improving outcomes for patients.
Meanwhile, at the National Institutes of Health Clinical Center located in Bethesda, Maryland researchers are actively conducting three clinical trials focusing on anal cancer. Having initiated their very first trial in 2018 as well and completing five studies overall thus far; this center showcases its dedication toward understanding and combatting this particular form of cancer.
In Edmonton Canada's Cross Cancer Institute has been diligently working on adding up scientific insight regarding anal cancer through two current investigational methods while having conducted just as many tests since embarking upon them lately back from2018 reflecting an enthusiasm driving progress here too!
Finally joining these institutions Anchorage Associates in Radiation Medicine situated amidst Alaska's breathtaking landscape come forward with equal vigor contributing by running two currently running experiments dealing with such delicate cases concerning our topic; however like other testing facilities mentioned earlier theirs can be traced back only till recent years namely2018 but nevertheless holds great potential expanding avenues facilitating improvisation when it comes down fighting against diseases like these .
These hospitals demonstrate that even though resources might vary or some efforts relatively newer compared to others.The collective pursuit towards conquering anal cancers remains unyielding across geographical boundaries.Throughout these locations we see how healthcare professionals around world continue striving relentlessly bringing us closer each day,to better treatments which promise brighter futures for patients affected by anal cancer.
Which are the best cities for anal cancer clinical trials?
When it comes to anal cancer clinical trials, several cities in the United States are at the forefront of research. Los Angeles, California leads with 16 active trials studying treatments like Nivolumab and pembrolizumab. Anchorage, Alaska follows closely behind with 15 ongoing studies focusing on interventions such as Nivolumab and Intensity-Modulated Radiation Therapy. Additionally, Houston, Texas has 10 active trials investigating factors like prior HPV for Anal Neoplasia and pembrolizumab. These cities offer individuals battling anal cancer access to cutting-edge clinical trials that contribute to advancements in care and improve outcomes.
Which are the top treatments for anal cancer being explored in clinical trials?
Exciting advancements are being made in the realm of anal cancer treatment, with several potential breakthroughs currently being explored in clinical trials. Leading the pack is nivolumab, a drug that is undergoing testing in four active trials specifically focused on anal cancer. Since its initial listing in 2015, it has been involved in a total of four clinical trials for this disease. Also showing promise is M7824, which is being investigated through two ongoing trials and has been featured in three previous anal cancer studies since its introduction in 2018. In addition to these targeted treatments, research also indicates the potential benefits of discontinuing PD-1/PD-L1 inhibitors and utilizing the 9-valent HPV vaccination as strategies for managing anal cancer progression. As these innovative approaches continue to undergo rigorous examination, they hold great hope for improving outcomes and quality of life for those affected by anal cancer.
What are the most recent clinical trials for anal cancer?
Exciting developments in the realm of anal cancer research offer new hope and potential treatment options for patients. Amongst the most recent clinical trials is a study investigating reduced elective dose combined with concurrent capecitabine/mitomycin C, which aims to improve outcomes for individuals battling this type of cancer. Additionally, another trial focuses on chemo-radiation treatment as a potential approach to managing anal cancer. Promising results have also been observed in a phase 2 trial exploring E7 TCR-T cells as an innovative therapy for this condition. Furthermore, single-agent KFA115 shows promise as a potential treatment option based on early-phase studies. Lastly, ongoing investigation into the effectiveness of 9-valent HPV vaccination provides further avenues for prevention and management strategies related to anal cancer. These groundbreaking trials hold great promise and may lead to significant advancements in treating anal cancer.
What anal cancer clinical trials were recently completed?
Several notable clinical trials focusing on anal cancer have recently been completed, signifying important advancements in the field of treatment. In May 2019, Xencor, Inc. wrapped up a trial investigating XmAb®22841 therapy for this specific type of cancer. Another significant trial was completed in November 2018 by M.D. Anderson Cancer Center, which explored the potential benefits of Linear Energy Transfer-Optimized Intensity Modulated Proton Therapy. Additionally, Xencor conducted a study on XmAb20717 that concluded in July 2018. Finally, the National Cancer Institute's trial examining M7824 reached its completion milestone in February 2018. These successful trials contribute to our understanding and future management approaches for anal cancer patients and highlight ongoing efforts towards improved treatments.